Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 124

Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2012', provides an overview of the Bipolar Disorder (Manic Depression) therapeutic pipeline. This report provides information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression). 'Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bipolar Disorder (Manic Depression).
- A review of the Bipolar Disorder (Manic Depression) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Bipolar Disorder (Manic Depression) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bipolar Disorder (Manic Depression) Therapeutic Products under Development, Key Players in Bipolar Disorder (Manic Depression) Therapeutics, Bipolar Disorder (Manic Depression) Pipeline Overview, Bipolar Disorder (Manic Depression) Pipeline, Bipolar Disorder (Manic Depression) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bipolar Disorder (Manic Depression) Overview
Therapeutics Development
An Overview of Pipeline Products for Bipolar Disorder (Manic Depression)
Bipolar Disorder (Manic Depression) Therapeutics under Development by Companies
Bipolar Disorder (Manic Depression) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Bipolar Disorder (Manic Depression) Therapeutics – Products under Development by Companies
Bipolar Disorder (Manic Depression) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Bipolar Disorder (Manic Depression) Therapeutics Development
DURECT Corporation
AstraZeneca PLC
Eli Lilly and Company
Dainippon Sumitomo Pharma Co., Ltd.
Alexza Pharmaceuticals, Inc.
Astellas Pharma Inc.
Cephalon, Inc.
Gedeon Richter Plc.
IntelGenx Technologies Corp.
Jazz Pharmaceuticals, Inc.
Repligen Corporation
Biotie Therapies Corp.
D-Pharm Ltd.
Omeros Corporation
Marinus Pharmaceuticals, Inc.
KemPharm, Inc.
Naurex, Inc.
Bipolar Disorder (Manic Depression) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Nuvigil - Drug Profile
Latuda - Drug Profile
FK949E - Drug Profile
Cariprazine - Drug Profile
SYN-111 - Drug Profile
RG2417 - Drug Profile
Adasuve - Drug Profile
JZP-4 - Drug Profile
KP303 - Drug Profile
Taurine - Drug Profile
Riluzole - Drug Profile
DP-VPA - Drug Profile
RU-486 - Drug Profile
Acetyl-L-Carnitine + Alpha-Lipoic Acid - Drug Profile
Valacyclovir - Drug Profile
Seroquel XR + Pramipexole - Drug Profile
Lisdexamfetamine - Drug Profile
Rilutek - Drug Profile
Mirapex - Drug Profile
Ketamine - Drug Profile
Scopolamine - Drug Profile
Celexa - Drug Profile
Lamotrigine + Antidepressant Therapy - Drug Profile
Recombinant Human Erythropoietin - Drug Profile
Ceftriaxone - Drug Profile
Tamoxifen - Drug Profile
Provera - Drug Profile
Digibind - Drug Profile
Chelerythrine - Drug Profile
Valproate + Risperidone - Drug Profile
Naltrexone + Valproate - Drug Profile
Liothyronine - Drug Profile
Sertraline + Lithium Carbonate - Drug Profile
Oral Uridine - Drug Profile
Abilify - Drug Profile
Quetiapine XR - Drug Profile
Mifepristone - Drug Profile
Divalproex ER - Drug Profile
Lamictal - Drug Profile
LY2979165 - Drug Profile
AZD4451 - Drug Profile
Quetiapine - Drug Profile
Valproate + Memantine - Drug Profile
INT0022 - Drug Profile
Latuda + Lithium - Drug Profile
NP03 - Drug Profile
NRX-1050 Series - Drug Profile
Relday - Drug Profile
GPR78 Antagonist - Drug Profile
Bipolar Disorder (Manic Depression) Therapeutics – Drug Profile Updates
Bipolar Disorder (Manic Depression) Therapeutics – Discontinued Products
Bipolar Disorder (Manic Depression) Therapeutics - Dormant Products
Bipolar Disorder (Manic Depression) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bipolar Disorder (Manic Depression), H1 2012
Products under Development for Bipolar Disorder (Manic Depression) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
DURECT Corporation, H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
Dainippon Sumitomo Pharma Co., Ltd., H1 2012
Alexza Pharmaceuticals, Inc., H1 2012
Astellas Pharma Inc., H1 2012
Cephalon, Inc., H1 2012
Gedeon Richter Plc., H1 2012
IntelGenx Technologies Corp., H1 2012
Jazz Pharmaceuticals, Inc., H1 2012
Repligen Corporation, H1 2012
Biotie Therapies Corp., H1 2012
D-Pharm Ltd., H1 2012
Omeros Corporation, H1 2012
Marinus Pharmaceuticals, Inc., H1 2012
KemPharm, Inc., H1 2012
Naurex, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Bipolar Disorder (Manic Depression) Therapeutics – Drug Profile Updates
Bipolar Disorder (Manic Depression) Therapeutics – Discontinued Products
Bipolar Disorder (Manic Depression) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Bipolar Disorder (Manic Depression), H1 2012
Products under Development for Bipolar Disorder (Manic Depression) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2013
• Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2012
• Bipolar Disorder (Event Driven)
• Major Depressive Disorder – Pipeline Review, H1 2013
• Gastric Motility Disorder - Pipeline Review, H1 2013
• Lysosomal Storage Disorder - Pipeline Review, H1 2013
• Key Findings from Treatment Algorithms: Bipolar Disorder
• Bipolar Disorder - Global Strategic Business Report
• Male Sexual Dysfunction - Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013